F2R and myeloproliferative neoplasm: Since a non-hemostatic, platelet-independent inhibitor, vorapaxar blocks the thrombin binding to the PAR1 receptor, the expression of cell surface PAR1 expression (%) in MPN CD34+ cells were determined to be significantly reduced after vorapaxar treatment (Fig. 3B).